UBS Group
CRDF icon

UBS Group’s Cardiff Oncology CRDF Stock Holding History

UBS Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$130K – 10284
2024
Q4 		$130K Buy
+30,000
New +$93.8K ﹤0.01% 6711

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

UBS Group's CRDF Position: Q2 2026 in Review

UBS Group increased its Cardiff Oncology (CRDF) stake by 59% in Q2 2026, buying an estimated $378K and bringing the position to 638,699 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #5886.

UBS Group first reported a position in CRDF in Q4 2014 and has held it in 45 quarters since. The position peaked at $1.23M in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • UBS Group held 638,699 shares of Cardiff Oncology worth $830K as of Q2 2026.
  • UBS Group bought 238,123 Cardiff Oncology shares in Q2 2026, an estimated $378K.
  • Cardiff Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5886 holding.
  • UBS Group first reported a position in Cardiff Oncology in Q4 2014 and has held it in 45 quarters since.
  • UBS Group's Cardiff Oncology position peaked at $1.23M in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.